Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.65 |
| ▸ | VEGFA | P15692 | 7/20 | 0.65 |
| ▸ | FLT1 | P17948 | 7/20 | 0.65 |
| ▸ | EGLN3 | Q9H6Z9 | 8/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | TET3 | O43151 | 1/20 | 0.40 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.40 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.40 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921504 | 0.79 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933438 | 0.78 | EGLN1 (0.67) | EGLN1VEGFAFLT1EGLN3ABL1 | |
| SCHEMBL3031405 | 0.77 | EGLN1 (0.63) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933420 | 0.77 | EGLN1 (0.63) | EGLN1VEGFAFLT1EGLN3ABL1 | |
| SCHEMBL19933401 | 0.77 | EGLN1 (0.66) | EGLN1VEGFAFLT1EGLN3ABL1 | |
| SCHEMBL19933386 | 0.75 | EGLN1 (0.77) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933427 | 0.75 | EGLN1 (0.54) | EGLN1VEGFAFLT1EGLN3ABL1 | |
| SCHEMBL3139000 | 0.70 | EGLN1 (0.85) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL4495649 | 0.70 | MAP4K4 (0.54) | EGLN1VEGFAFLT1ABL1MAP4K4 | |
| SCHEMBL14055208 | 0.69 | EGLN1 (0.49) | EGLN1VEGFAFLT1ABL1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.